share_log

C4 Therapeutics | 10-Q: Q3 2024 Earnings Report

C4 Therapeutics | 10-Q: Q3 2024 Earnings Report

C4 Therapeutics | 10-Q:2024財年三季報
美股SEC公告 ·  2024/10/31 11:15

牛牛AI助理已提取核心訊息

C4 Therapeutics reported Q3 2024 revenue of $15.4 million, up from $11.1 million in Q3 2023, driven by an $8.0 million milestone payment from Biogen and $6.9 million from new collaborations with MKDG, Merck and Betta Pharma. Net loss narrowed to $24.7 million compared to $27.0 million in the prior year quarter. Cash, cash equivalents and marketable securities totaled $284.4 million as of September 30, 2024.The company continues to advance its clinical programs, with positive data from cemsidomide (CFT7455) Phase 1/2 trial in multiple myeloma and non-Hodgkin lymphomas. CFT1946 showed proof of mechanism in BRAF V600 mutant solid tumors at ESMO 2024. Strategic collaborations expanded with new partnerships with MKDG ($16 million upfront) and Merck ($10 million upfront) for protein degrader development.Research and development expenses increased to $31.8 million in Q3 2024 from $28.3 million in Q3 2023, primarily due to clinical trial progress. The company implemented a restructuring plan in January 2024 reducing workforce by 30% to optimize costs. Management expects current cash runway to fund operations into 2027 based on existing programs and partnerships.
C4 Therapeutics reported Q3 2024 revenue of $15.4 million, up from $11.1 million in Q3 2023, driven by an $8.0 million milestone payment from Biogen and $6.9 million from new collaborations with MKDG, Merck and Betta Pharma. Net loss narrowed to $24.7 million compared to $27.0 million in the prior year quarter. Cash, cash equivalents and marketable securities totaled $284.4 million as of September 30, 2024.The company continues to advance its clinical programs, with positive data from cemsidomide (CFT7455) Phase 1/2 trial in multiple myeloma and non-Hodgkin lymphomas. CFT1946 showed proof of mechanism in BRAF V600 mutant solid tumors at ESMO 2024. Strategic collaborations expanded with new partnerships with MKDG ($16 million upfront) and Merck ($10 million upfront) for protein degrader development.Research and development expenses increased to $31.8 million in Q3 2024 from $28.3 million in Q3 2023, primarily due to clinical trial progress. The company implemented a restructuring plan in January 2024 reducing workforce by 30% to optimize costs. Management expects current cash runway to fund operations into 2027 based on existing programs and partnerships.
C4 Therapeutics發佈了2024年第三季度營業收入爲1540萬美元,較2023年第三季度的1110萬美元增長,主要得益於來自渤健公司800萬美元的里程碑付款以及來自MKDG、默沙東和貝達藥業的690萬美元的新合作。淨虧損縮窄至2470萬美元,相較於上一年同期的2700萬美元。截止到2024年9月30日,現金、現金等價物和金融資產總額爲28440萬美元。該公司繼續推進其臨牀項目,cemsidomide(CFT7455)在多發性骨髓瘤和非霍奇金淋巴瘤的1/2期試驗中取得了積極的數據。CFT1946在2024年ESMO大會上顯示了在BRAF V600突變實體瘤中的機制證明。戰略合作通過與...展開全部
C4 Therapeutics發佈了2024年第三季度營業收入爲1540萬美元,較2023年第三季度的1110萬美元增長,主要得益於來自渤健公司800萬美元的里程碑付款以及來自MKDG、默沙東和貝達藥業的690萬美元的新合作。淨虧損縮窄至2470萬美元,相較於上一年同期的2700萬美元。截止到2024年9月30日,現金、現金等價物和金融資產總額爲28440萬美元。該公司繼續推進其臨牀項目,cemsidomide(CFT7455)在多發性骨髓瘤和非霍奇金淋巴瘤的1/2期試驗中取得了積極的數據。CFT1946在2024年ESMO大會上顯示了在BRAF V600突變實體瘤中的機制證明。戰略合作通過與MKDG(1600萬美元預付款)和默沙東(1000萬美元預付款)的新合作伙伴關係在蛋白質降解劑開發方面擴展。2024年第三季度的研發費用從2023年第三季度的2830萬美元增加至3180萬美元,主要由於臨牀試驗進展。該公司於2024年1月實施了一項重組計劃,裁減30%的員工以優化成本。管理層預計,基於現有項目和合作夥伴關係,當前的現金儲備可以支持運營到2027年。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 275

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。